<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923413</url>
  </required_header>
  <id_info>
    <org_study_id>14-018</org_study_id>
    <nct_id>NCT03923413</nct_id>
  </id_info>
  <brief_title>Endothelial Function and Circulating Microparticle in Patients Under LVAD Support</brief_title>
  <acronym>MP-LVAD</acronym>
  <official_title>Endothelial Function and Circulating Microparticle in Patients Under LVAD Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this project are 1) to evaluate whether circulating micraparticals (MPs) in
      patients with LVAD impair endothelial function and 2) to assess the procoagulative activity
      of circulating MPs in patients with LVAD in a prospective longitudinal study of patients
      undergoing LVAD implantation, 3) to analyze these parameters in the context of thromboembolic
      events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous-flow left ventricular assist devices (LVADs) have arised as a vital therapeutic
      option in end stage heart failure not merely as bridge-to transplant but also as destination
      therapy. LVADs are associated with impaired endothelial function as well as with a dysbalance
      of coagulation leading to both, excessive bleeding and thromboembolic events, respectively.
      Microparticles (MPs) are shed membrane particles budded into the circulation and considered
      as a marker of compromised endothelial integrity and enhanced procoagulation levels. In
      addition, MPs have been suggested to play an active role in the induction of endothelial
      dysfunction and coagulation. First studies demonstrated increased level of MPs in patients
      with LVAD. Whether circulating MPs contribute to impaired endothelial function and enhanced
      coagulation in patients with LVAD and thereby promote thrombotic complications is unknown.

      The aims of this project are 1) to evaluate whether circulating MPs in patients with LVAD
      impair endothelial function and 2) to assess the procoagulative activity of circulating MPs
      in patients with LVAD in a prospective longitudinal study of patients undergoing LVAD
      implantation, 3) to analyze these parameters in the context of thromboembolic events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of thrombemboic events during 12 month</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Baseline</time_frame>
    <description>Flow mediated dilatation measured by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of circulating mircoparticles</measure>
    <time_frame>Baseline</time_frame>
    <description>measured and discriminated by FACS and ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microparticle induced thrombin generation</measure>
    <time_frame>Baseline</time_frame>
    <description>measured and discriminated by FACS and ELISA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>End Stage Heart Failure</condition>
  <arm_group>
    <arm_group_label>patients with chronic heart failure without LVAD support</arm_group_label>
    <description>patients with chronic heart failure without LVAD support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with end-stage heart failure with LVAD support</arm_group_label>
    <description>patients with end-stage heart failure with LVAD support</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples for MP evaluation</description>
    <arm_group_label>patients with chronic heart failure without LVAD support</arm_group_label>
    <arm_group_label>patients with end-stage heart failure with LVAD support</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      3ml venous blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the heart failure program of the University of Duesseldorf
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria: chronic heart failure INTERMASC 5-7 or

          -  Patients on LVAD support

        Exclusion Criteria:

          -  current thrombembolic or bleeding event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Heinrich-Heine-University, Div. of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Dusseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik f√ºr Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Dr.med. Patrick Horn, Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>circulating MP</keyword>
  <keyword>FMD</keyword>
  <keyword>LVAD</keyword>
  <keyword>endothelial function</keyword>
  <keyword>endothelial integrity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

